glp 1 drug zepbound GLP1 Use For Weight Loss Has Soared Costing Billions Dual GIP/GLP-1 Drug Linked to

Description

In particular, in a RCT in women with PCOS with BMI 25 kg/m 2 and/or insulin resistance, Frssing et al

Key findings from published and presented studies include: In a phase 2 obesity trial, higherdose retatrutide produced average weight loss of around 22.824.2% over 48 weeks in people with obesity. In participants with type 2 diabetes, retatrutide achieved substantial weight loss and marked improvements in blood sugar and cardiometabolic markers, though average percentage weight loss was somewhat lower than in nondiabetic obesity cohorts. Early studies also reported significant reductions in liver fat and visceral adipose tissue, with a high proportion of participants with fatty liver disease showing resolution of hepatic steatosis at higher doses. These results have led several reviews to describe retatrutide as a potential game changer in obesity pharmacotherapy, representing the first GLP1/GIP/glucagon triple agonist with robust human data. Popular coverage has highlighted phase 3 data suggesting average weight losses approaching 29% of body weight in some cohorts (roughly 71 pounds), which is about double typical results with semaglutide over comparable periods

Ozempic Common potential side effects of phentermine may include: Dry mouth or altered taste Stomach problems (constipation or diarrhea) Heart palpitations or fast heart rate Dizziness Shaking (tremors) Headache Sexual problems Increased blood pressure Restlessness or overstimulation Difficulty sleeping Mood changes (euphoria or dysphoria) Psychosis (disconnection from reality, including hallucinations or delusions) Ozempic is generally associated with gastrointestinal issues